Vertex Pharmaceuticals (VRTX) Total Liabilities (2009 - 2026)
Vertex Pharmaceuticals' quarterly Total Liabilities came in at $7.1 billion in Q1 2026, up 11.56% year-on-year from $6.4 billion in Q1 2025, and up 2.08% quarter-over-quarter from $7.0 billion in Q4 2025.
Vertex Pharmaceuticals has reported Total Liabilities for 18 years, with the latest figure at $7.1 billion in Q1 2026.
- For the quarter ending Q1 2026, Total Liabilities rose 11.56% year-over-year to $7.1 billion; the trailing twelve-month figure through Mar 2026 stood at $7.1 billion (up 11.56% YoY), and the FY2025 full-year result was $7.0 billion, up 13.94% from the prior year.
- Total Liabilities for Q1 2026 stood at $7.1 billion, up from $7.0 billion in the prior quarter.
- The five-year high for Total Liabilities was $7.5 billion in Q3 2025, with the low at $3.3 billion in Q1 2022.
- Average Total Liabilities over 5 years is $5.5 billion, with a median of $5.4 billion recorded in 2024.
- Year-over-year, Total Liabilities climbed 6.84% in 2022 and jumped 41.79% in 2023.
- Tracing VRTX's Total Liabilities over 5 years: stood at $4.2 billion in 2022, then advanced by 21.51% to $5.1 billion in 2023, then climbed by 18.91% to $6.1 billion in 2024, then climbed by 13.94% to $7.0 billion in 2025, then rose by 2.08% to $7.1 billion in 2026.
- The last three Total Liabilities figures came in at $7.1 billion (Q1 2026), $7.0 billion (Q4 2025), and $7.5 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 753.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.12 Bn |
| Dec 31, 2025 | 6.98 Bn |
| Sep 30, 2025 | 7.54 Bn |
| Jun 30, 2025 | 6.86 Bn |
| Mar 31, 2025 | 6.38 Bn |
| Dec 31, 2024 | 6.12 Bn |
| Sep 30, 2024 | 6.61 Bn |
| Jun 30, 2024 | 5.36 Bn |
| Mar 31, 2024 | 5.37 Bn |
| Dec 31, 2023 | 5.15 Bn |
| Sep 30, 2023 | 5.21 Bn |
| Jun 30, 2023 | 4.88 Bn |
| Mar 31, 2023 | 4.54 Bn |
| Dec 31, 2022 | 4.24 Bn |
| Sep 30, 2022 | 3.68 Bn |
| Jun 30, 2022 | 3.65 Bn |
| Mar 31, 2022 | 3.35 Bn |
| Dec 31, 2021 | 3.33 Bn |
| Sep 30, 2021 | 3.09 Bn |
| Jun 30, 2021 | 3.03 Bn |
| Mar 31, 2021 | 3.13 Bn |
| Dec 31, 2020 | 3.07 Bn |
| Sep 30, 2020 | 3.17 Bn |
| Jun 30, 2020 | 2.70 Bn |
| Mar 31, 2020 | 2.43 Bn |
| Dec 31, 2019 | 2.23 Bn |
| Sep 30, 2019 | 2.26 Bn |
| Jun 30, 2019 | 1.96 Bn |
| Mar 31, 2019 | 1.82 Bn |
| Dec 31, 2018 | 1.81 Bn |
| Sep 30, 2018 | 1.69 Bn |
| Jun 30, 2018 | 1.62 Bn |
| Mar 31, 2018 | 1.52 Bn |
| Dec 31, 2017 | 1.50 Bn |
| Sep 30, 2017 | 1.40 Bn |
| Jun 30, 2017 | 1.42 Bn |
| Mar 31, 2017 | 1.26 Bn |
| Dec 31, 2016 | 1.56 Bn |
| Sep 30, 2016 | 1.40 Bn |
| Jun 30, 2016 | 1.38 Bn |
| Mar 31, 2016 | 1.37 Bn |
| Dec 31, 2015 | 1.40 Bn |
| Sep 30, 2015 | 1.36 Bn |
| Jun 30, 2015 | 1.33 Bn |
| Mar 31, 2015 | 1.17 Bn |
| Dec 31, 2014 | 1.24 Bn |
| Sep 30, 2014 | 1.25 Bn |
| Jun 30, 2014 | 945.55 Mn |
| Mar 31, 2014 | 966.23 Mn |
| Dec 31, 2013 | 962.64 Mn |
| Sep 30, 2013 | 1.10 Bn |
| Jun 30, 2013 | 1.04 Bn |
| Mar 31, 2013 | 1.42 Bn |
| Dec 31, 2012 | 1.52 Bn |
| Sep 30, 2012 | 1.45 Bn |
| Jun 30, 2012 | 1.36 Bn |
| Mar 31, 2012 | 1.24 Bn |
| Dec 31, 2011 | 1.24 Bn |
| Sep 30, 2011 | 1.36 Bn |
| Mar 31, 2011 | 1.15 Bn |
| Dec 31, 2010 | 1.22 Bn |
| Sep 30, 2010 | 1.24 Bn |
| Jun 30, 2010 | 827.07 Mn |
| Mar 31, 2010 | 779.69 Mn |
| Dec 31, 2009 | 859.14 Mn |